Athos Capital’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

Athos Capital’s Portfolio OACCU Stock Details OACCU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$550K	Hold	50,000	–	–	0.2%	26
2026 Q1	$534K	Hold	50,000	–	–	0.16%	28
2025 Q4	$536K	Hold	50,000	–	–	0.21%	23
2025 Q3	$533K	Hold	50,000	–	–	0.33%	18
2025 Q2	$531K	Hold	50,000	–	–	0.79%	20
2025 Q1	$522K	Hold	50,000	–	–	0.62%	28
2024 Q4	$507K	Buy	+50,000	New	+$504K	0.23%	23

Other funds holding OACCU

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Athos Capital's OACCU Position: Q2 2026 in Review

Athos Capital held its Oaktree Acquisition Corp III Life Sciences Unit (OACCU) position steady in Q2 2026 at 50,000 shares worth $550K. The position accounts for 0.2% of the portfolio, ranked #26.

Athos Capital first reported a position in OACCU in Q4 2024 and has held it in 7 quarters since. 5 funds tracked by Wall St. Rank hold OACCU as of Q2 2026.

Athos Capital held 50,000 shares of Oaktree Acquisition Corp III Life Sciences Unit worth $550K as of Q2 2026.
Athos Capital left its Oaktree Acquisition Corp III Life Sciences Unit share count unchanged in Q2 2026.
Oaktree Acquisition Corp III Life Sciences Unit made up 0.2% of Athos Capital's portfolio in Q2 2026, its #26 holding.
Athos Capital first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q4 2024 and has held it in 7 quarters since.
5 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q2 2026.

Based on Athos Capital's 13F filing for Q2 2026, filed 13 Aug 2026.